Rorer/NNP Group/NNP Inc./NNP will/MD report/VB that/IN third-quarter/JJ profit/NN rose/VBD more/RBR than/IN #/CD %/NN from/IN a/DT year/NN earlier/RBR ,/, though/IN the/DT gain/NN is/VBZ wholly/RB due/JJ to/TO asset/NN sales/NNS ,/, Robert/NNP Cawthorn/NNP ,/, chairman/NN ,/, president/NN and/CC chief/JJ executive/JJ officer/NN ,/, said/VBD ./.
His/PRP$ projection/NN indicates/VBZ profit/NN in/IN the/DT latest/JJS quarter/NN of/IN more/JJR than/IN $/$ #.#/CD million/CD ,/, or/CC #/CD cents/NNS a/DT share/NN ,/, compared/VBN with/IN $/$ #.#/CD million/CD ,/, or/CC #/CD cents/NNS a/DT share/NN ,/, a/DT year/NN ago/RB ./.
Mr./NNP Cawthorn/NNP said/VBD in/IN an/DT interview/NN that/IN sales/NNS will/MD show/VB an/DT increase/NN from/IN a/DT year/NN ago/RB of/IN ``/`` somewhat/RB less/JJR than/IN #/CD %/NN ./. ''/''
Through/IN the/DT first/JJ six/CD months/NNS of/IN #/CD ,/, sales/NNS had/VBD grown/VBN about/RB #/CD %/NN from/IN the/DT year-earlier/JJ period/NN ./.
Growth/NN of/IN #/CD %/NN would/MD make/VB sales/NNS for/IN the/DT latest/JJS quarter/NN $/$ #/CD million/CD ,/, compared/VBN with/IN $/$ #.#/CD million/CD a/DT year/NN ago/RB ./.
Mr./NNP Cawthorn/NNP said/VBD the/DT profit/NN growth/NN in/IN the/DT latest/JJS quarter/NN was/VBD due/JJ to/TO the/DT sale/NN of/IN two/CD Rorer/NNP drugs/NNS ./.
Asilone/NNP ,/, an/DT antacid/NN ,/, was/VBD sold/VBN to/TO Boots/NNP PLC/NNP ,/, London/NNP ./.
Thrombinar/NNP ,/, a/DT drug/NN used/VBN to/TO stanch/VB bleeding/NN ,/, was/VBD sold/VBN to/TO Jones/NNP Medical/NNP Industries/NNP Inc./NNP ,/, St./NNP Louis/NNP ./.
He/PRP said/VBD Rorer/NNP sold/VBD the/DT drugs/NNS for/IN ``/`` nice/JJ prices/NNS ''/'' and/CC will/MD record/VB a/DT combined/VBN ,/, pretax/JJ gain/NN on/IN the/DT sales/NNS of/IN $/$ #/CD million/CD ./.
As/IN the/DT gain/NN from/IN the/DT sales/NNS indicates/VBZ ,/, operating/NN profit/NN was/VBD ``/`` significantly/RB ''/'' below/IN the/DT year-earlier/JJ level/NN ,/, Mr./NNP Cawthorn/NNP said/VBD ./.
Rorer/NNP in/IN July/NNP had/VBD projected/VBN lower/JJR third-quarter/JJ operating/NN profit/NN but/CC higher/JJR profit/NN for/IN all/DT of/IN #/CD ./.
He/PRP said/VBD the/DT company/NN is/VBZ still/RB looking/VBG for/IN ``/`` a/DT strong/JJ fourth/JJ quarter/NN in/IN all/DT areas/NNS --/: sales/NNS ,/, operating/NN income/NN and/CC net/JJ income/NN ./. ''/''
Mr./NNP Cawthorn/NNP attributed/VBD the/DT decline/NN in/IN third-quarter/JJ operating/NN profit/NN to/TO the/DT stronger/JJR dollar/NN ,/, which/WDT reduces/VBZ the/DT value/NN of/IN overseas/JJ profit/NN when/WRB it/PRP is/VBZ translated/VBN into/IN dollars/NNS ;/: to/TO accelerated/VBN buying/NN of/IN Rorer/NNP products/NNS in/IN the/DT second/JJ quarter/NN because/IN of/IN a/DT then-pending/JJ July/NNP #/CD price/NN increase/NN ,/, and/CC to/TO higher/JJR marketing/NN expenses/NNS for/IN Rorer/NNP 's/POS Maalox/NNP antacid/NN ,/, whose/WP$ sales/NNS and/CC market/NN share/NN in/IN the/DT U.S./NNP had/VBD slipped/VBN in/IN the/DT first/JJ half/NN of/IN #/CD ./.
He/PRP said/VBD Rorer/NNP opted/VBD to/TO sell/VB Asilone/NNP and/CC Thrombinar/NNP to/TO raise/VB revenue/NN that/WDT would/MD ``/`` kick/NN start/VB ''/'' its/PRP$ increased/VBN marketing/NN efforts/NNS behind/IN Maalox/NNP ,/, still/RB its/PRP$ top-selling/JJ product/NN with/IN about/RB $/$ #/CD million/CD in/IN world-wide/JJ sales/NNS in/IN #/CD ./.
``/`` We/PRP had/VBD underfunded/VBN Maalox/NNP for/IN a/DT year/NN ,/, ''/'' he/PRP said/VBD ,/, because/IN the/DT company/NN was/VBD concentrating/VBG on/IN research/NN and/CC development/NN and/CC promoting/VBG other/JJ drugs/NNS ./.
He/PRP said/VBD Rorer/NNP will/MD spend/VB $/$ #/CD million/CD to/TO $/$ #/CD million/CD more/JJR on/IN Maalox/NNP advertising/NN and/CC promotion/NN in/IN the/DT second/JJ half/NN of/IN #/CD than/IN in/IN the/DT year-earlier/JJ period/NN ./.
A/DT ``/`` big/JJ chunk/NN ''/'' of/IN that/DT additional/JJ spending/NN came/VBD in/IN the/DT third/JJ quarter/NN ,/, he/PRP said/VBD ./.
